Ensysce Biosciences (ENSC) Total Liabilities (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Total Liabilities for 9 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Liabilities rose 106.0% year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was $4.6 million, a 106.0% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, up 106.0% from the prior year.
• Total Liabilities was $4.6 million for Q4 2025 at Ensysce Biosciences, up from $2.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $24.6 million in Q4 2021 and troughed at $1.3 million in Q2 2024.
• A 5-year average of $6.3 million and a median of $3.7 million in 2021 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 250.56% in 2021 and tumbled 85.99% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $24.6 million in 2021, then slumped by 59.66% to $9.9 million in 2022, then plunged by 66.12% to $3.4 million in 2023, then sank by 34.0% to $2.2 million in 2024, then surged by 106.0% to $4.6 million in 2025.
• The last three Total Liabilities figures came in at $4.6 million (Q4 2025), $2.3 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.